Profile data is unavailable for this security.
About the company
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
- Revenue in USD (TTM)0.00
- Net income in USD-25.97m
- Incorporated2008
- Employees17.00
- LocationGeoVax Labs Inc1900 Lake Park Drive, Suite 380SMYRNA 30080United StatesUSA
- Phone+1 (678) 384-7220
- Fax+1 (302) 655-5049
- Websitehttps://www.geovax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc | 420.00k | -22.76m | 3.38m | 12.00 | -- | 4.03 | -- | 8.05 | -26.72 | -26.72 | 0.4924 | 0.5732 | 0.0228 | -- | 0.1106 | -- | -122.40 | -57.58 | -212.95 | -69.81 | -- | -- | -5,370.24 | -18,789.29 | -- | -170.83 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Mustang Bio Inc | 0.00 | -51.60m | 3.38m | 80.00 | -- | 21.18 | -- | -- | -6.15 | -6.15 | 0.00 | 0.0128 | 0.00 | -- | -- | 0.00 | -93.68 | -70.02 | -129.52 | -79.98 | -- | -- | -- | -- | -- | -15.56 | 0.00 | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Axim Biotechnologies Inc | 39.77k | -8.06m | 3.44m | 6.00 | -- | -- | -- | 86.48 | -0.0366 | -0.0366 | 0.0001 | -0.0311 | 0.0095 | -- | -- | 6,628.33 | -193.43 | -154.34 | -- | -390.73 | -- | -- | -20,265.75 | -36,362.71 | -- | -0.62 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Aditxt Inc | 645.19k | -32.70m | 3.45m | 47.00 | -- | 0.17 | -- | 5.34 | -153.12 | -153.12 | 2.14 | 12.17 | 0.0233 | 0.8927 | 1.38 | 13,727.45 | -117.12 | -192.78 | -251.19 | -321.59 | -17.30 | -- | -5,020.30 | -7,208.65 | 0.2382 | -4.09 | 0.5020 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -10.83m | 3.54m | 8.00 | -- | 0.3733 | -- | -- | -6.40 | -6.40 | 0.00 | 2.06 | 0.00 | -- | -- | 0.00 | -97.63 | -71.92 | -116.38 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Revelation Biosciences Inc | 0.00 | -120.25k | 3.59m | 9.00 | 0.0751 | 0.0876 | -- | -- | 29.29 | 29.29 | 0.00 | 25.13 | 0.00 | -- | -- | 0.00 | -1.36 | -- | -3.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Geovax Labs Inc | 0.00 | -25.97m | 3.67m | 17.00 | -- | 0.5455 | -- | -- | -14.25 | -14.25 | 0.00 | 2.91 | 0.00 | -- | -- | 0.00 | -127.82 | -108.34 | -160.47 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Atreca Inc | 0.00 | -97.76m | 3.69m | 90.00 | -- | 0.3427 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
| Theralink Technologies Inc | 635.46k | -13.50m | 3.69m | 16.00 | -- | -- | -- | 5.81 | -0.0027 | -0.0027 | 0.00006 | -0.0093 | 0.2525 | -- | 13.51 | 39,716.25 | -536.39 | -- | -- | -- | 73.50 | -- | -2,124.10 | -- | -- | -1.35 | -- | -- | 6.85 | -- | -138.38 | -- | -- | -- |
| Yield10 Bioscience Inc | 60.00k | -14.46m | 3.77m | 29.00 | -- | -- | -- | 62.86 | -50.04 | -50.04 | 0.1815 | -4.95 | 0.01 | -- | 4.00 | 2,068.97 | -241.08 | -91.26 | -524.02 | -108.09 | -- | -- | -24,091.67 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| Navidea Biopharmaceuticals Inc | 610.00 | -8.81m | 3.80m | 11.00 | -- | -- | -- | 6,234.77 | -0.2086 | -0.0547 | 0.00001 | -0.0327 | 0.0001 | 0.1529 | 0.0066 | 55.45 | -143.97 | -169.68 | -- | -753.52 | -8,103.28 | 91.34 | -1,411,062.00 | -1,938.53 | 0.5066 | -- | -- | -- | -87.65 | -48.49 | -46.75 | -- | 63.23 | -- |
| 4Cable TV International Inc | 758.68k | -3.14m | 3.81m | 0.00 | -- | -- | -- | 5.03 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.81m | 40.00 | -- | 0.1032 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Data as of May 09 2024. Currency figures normalised to GeoVax Labs Inc's reporting currency: US Dollar USD
9.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 108.44k | 4.99% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 48.56k | 2.24% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 27.56k | 1.27% |
| Geode Capital Management LLCas of 31 Dec 2023 | 11.53k | 0.53% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.53k | 0.30% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 2.28k | 0.11% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.91k | 0.09% |
| Tower Research Capital LLCas of 31 Dec 2023 | 684.00 | 0.03% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 267.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 136.00 | 0.01% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
